UA107812C2 - ДВОЗАМІЩЕНІ ОКТАГІДРОПІРОЛО$3,4-с]ПІРОЛИ ЯК МОДУЛЯТОРИ ОРЕКСИНОВИХ РЕЦЕПТОРІВ - Google Patents

ДВОЗАМІЩЕНІ ОКТАГІДРОПІРОЛО$3,4-с]ПІРОЛИ ЯК МОДУЛЯТОРИ ОРЕКСИНОВИХ РЕЦЕПТОРІВ

Info

Publication number
UA107812C2
UA107812C2 UAA201206182A UAA201206182A UA107812C2 UA 107812 C2 UA107812 C2 UA 107812C2 UA A201206182 A UAA201206182 A UA A201206182A UA A201206182 A UAA201206182 A UA A201206182A UA 107812 C2 UA107812 C2 UA 107812C2
Authority
UA
Ukraine
Prior art keywords
modulators
octahydropyrolo
pyrols
dual
substituted
Prior art date
Application number
UAA201206182A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Wenying Chai
Michael A Letavic
Kiev S Ly
Daniel J Pippel
Dale A Rudolph
Kathleen C Sappey
Brad M Savall
Chandravadan R Shan
Brock T Shireman
Akinola Soyode-Jonson
Emily M Stocking
Devin M Swanson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UA107812C2 publication Critical patent/UA107812C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201206182A 2009-10-23 2010-10-21 ДВОЗАМІЩЕНІ ОКТАГІДРОПІРОЛО$3,4-с]ПІРОЛИ ЯК МОДУЛЯТОРИ ОРЕКСИНОВИХ РЕЦЕПТОРІВ UA107812C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25450909P 2009-10-23 2009-10-23
PCT/US2010/053606 WO2011050198A1 (en) 2009-10-23 2010-10-21 Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators

Publications (1)

Publication Number Publication Date
UA107812C2 true UA107812C2 (xx) 2015-02-25

Family

ID=43385633

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201206182A UA107812C2 (xx) 2009-10-23 2010-10-21 ДВОЗАМІЩЕНІ ОКТАГІДРОПІРОЛО$3,4-с]ПІРОЛИ ЯК МОДУЛЯТОРИ ОРЕКСИНОВИХ РЕЦЕПТОРІВ

Country Status (38)

Country Link
US (8) USRE48841E1 (enExample)
EP (3) EP3093291B1 (enExample)
JP (1) JP5759470B2 (enExample)
KR (3) KR101859400B1 (enExample)
CN (1) CN102781942B (enExample)
AR (2) AR078731A1 (enExample)
AU (2) AU2010310595B2 (enExample)
BR (1) BR112012010820B1 (enExample)
CA (1) CA2778484C (enExample)
CL (1) CL2010001162A1 (enExample)
CO (1) CO6541572A2 (enExample)
CR (1) CR20120273A (enExample)
CY (2) CY1117743T1 (enExample)
DK (2) DK3093291T3 (enExample)
EA (1) EA022766B1 (enExample)
EC (1) ECSP12011908A (enExample)
ES (2) ES2735411T3 (enExample)
HR (2) HRP20160781T1 (enExample)
HU (2) HUE043962T2 (enExample)
IL (1) IL219234A (enExample)
JO (2) JO3267B1 (enExample)
LT (1) LT3093291T (enExample)
ME (2) ME02437B (enExample)
MX (1) MX2012004753A (enExample)
NI (1) NI201200062A (enExample)
NZ (1) NZ599629A (enExample)
PE (1) PE20110404A1 (enExample)
PH (1) PH12012500796A1 (enExample)
PL (2) PL2491038T3 (enExample)
PT (2) PT2491038T (enExample)
RS (2) RS54945B1 (enExample)
SI (2) SI3093291T1 (enExample)
SM (2) SMT201900392T1 (enExample)
TR (1) TR201910327T4 (enExample)
TW (1) TWI481613B (enExample)
UA (1) UA107812C2 (enExample)
UY (1) UY32966A (enExample)
WO (1) WO2011050198A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2735411T3 (es) 2009-10-23 2019-12-18 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
EP2776430B1 (en) 2011-11-08 2016-03-16 Actelion Pharmaceuticals Ltd. 2- (1,2,3-triazol-2-yl) benzamide and 3-(1,2,3-triazol-2-yl) picolinamide derivatives as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체
CA2882132C (en) * 2012-08-16 2021-07-06 The Scripps Research Institute Kappa opioid ligands
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
CN103012293A (zh) * 2012-12-13 2013-04-03 同济大学 一种抗失眠药物mk-4305中间体的合成方法
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
WO2015003002A1 (en) * 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
MY179605A (en) 2013-12-04 2020-11-11 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
WO2016020403A1 (en) * 2014-08-04 2016-02-11 Sandoz Ag Preparation of a benzoic acid derivative and its use for the preparation of suvorexant
ES2901418T3 (es) 2014-08-13 2022-03-22 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores del receptor de orexina
US9611262B2 (en) 2014-09-11 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
WO2017088731A1 (zh) * 2015-11-24 2017-06-01 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
SI3414241T1 (sl) 2016-02-12 2022-10-28 Astrazeneca Ab Halo-substituitani piperidini kot modulatorji receptorja oreksina
CA2960253A1 (en) 2016-03-10 2017-09-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
CN105949203B (zh) * 2016-05-24 2018-07-13 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
CN107759620B (zh) * 2016-08-16 2021-11-12 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN108299437B (zh) * 2017-01-13 2022-07-08 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
GB201702174D0 (en) * 2017-02-09 2017-03-29 Benevolentai Bio Ltd Orexin receptor antagonists
CA3059394C (en) 2017-05-03 2023-09-12 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
GB201707499D0 (en) * 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
GB201707504D0 (en) * 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
PE20200665A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
US11324724B2 (en) 2017-09-28 2022-05-10 Boehringer Ingelheim International Gmbh N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides
CN109988171A (zh) * 2017-12-29 2019-07-09 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109988169B (zh) * 2017-12-29 2022-02-01 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109988170B (zh) * 2017-12-29 2022-04-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
US20210169883A1 (en) * 2018-07-27 2021-06-10 Icahn School Of Medicine At Mount Sinai Method of treating aggression with orexin receptor antagonists
WO2020100011A1 (en) * 2018-11-14 2020-05-22 Janssen Pharmaceutica Nv Improved synthetic methods of making fused heterocyclic compounds as orexin receptor modulators
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN112142713A (zh) * 2019-06-27 2020-12-29 山东润博生物科技有限公司 一种咪草烟的合成方法
JP7672386B2 (ja) * 2019-08-07 2025-05-07 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節薬としての（２ｈ－１，２，３－トリアゾール－２－イル）フェニル化合物の改善された合成方法
CN112876479B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
WO2021104294A1 (en) * 2019-11-29 2021-06-03 Sunshine Lake Pharma Co., Ltd. CRYSTAL FORMS OF OCTAHYDROPYRROLO [3,4-c] PYRROLE DERIVATIVES
CN112876481B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
CN112876478B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
CN112876480B (zh) * 2019-11-29 2022-07-26 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物的晶型
WO2022122009A1 (zh) * 2020-12-11 2022-06-16 苏州晶云药物科技股份有限公司 吡咯类衍生化合物的晶型及其制备方法
WO2022194122A1 (zh) * 2021-03-16 2022-09-22 上海翰森生物医药科技有限公司 含氮杂环的多环化合物及其制备方法和应用
CN114063673B (zh) * 2021-11-09 2023-03-03 万华化学集团股份有限公司 一种反应釜温度控制方法、系统及存储介质
CN116217593B (zh) * 2021-12-02 2025-05-09 江苏恩华药业股份有限公司 一种八氢吡咯并[3,4-c]吡咯甲基酮衍生物及其应用
WO2023163964A1 (en) 2022-02-24 2023-08-31 Teva Czech Industries S.R.O. Solid state forms of seltorexant
WO2023180556A1 (en) 2022-03-24 2023-09-28 Janssen Pharmaceutica Nv Methods for treating agitation in subjects with mild cognitive impairment or major neurocognition disorder
IL318368A (en) * 2022-07-15 2025-03-01 Biogen Ma Inc Amofamyl-binding protein inhibitors and their uses
KR20250065855A (ko) * 2022-09-14 2025-05-13 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 질소 함유 헤테로고리의 다환식 화합물의 유리 염기 결정형 및 이의 제조 방법
CN120699043A (zh) * 2022-11-23 2025-09-26 江苏恩华药业股份有限公司 一种二取代八氢吡咯并[3,4-c]吡咯甲基酮衍生物及其应用
WO2024125395A1 (zh) * 2022-12-12 2024-06-20 江苏恩华药业股份有限公司 一种取代四氢环戊基[c]吡咯衍生物、制备方法、中间体及其应用
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators
WO2025003991A1 (en) 2023-06-29 2025-01-02 Janssen Pharmaceutica Nv Method of treating depression using seltorexant
CN120383601A (zh) * 2024-01-29 2025-07-29 成都康弘药业集团股份有限公司 食欲素受体调节剂及其制备方法和用途
WO2025242852A1 (en) 2024-05-24 2025-11-27 Janssen Pharmaceutica Nv Seltorexant for use in treating major depressive disorder with insomnia symptoms
CN118580243B (zh) * 2024-08-07 2025-01-03 艾斯拓康生物医药(天津)有限公司 一类含氮并环化合物及其制备方法和应用
CN119039301B (zh) * 2024-10-31 2025-09-02 江苏豪森药业集团有限公司 一种含氮杂环的多环化合物晶型ⅰ的制备方法

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
EP0871628A1 (en) 1995-06-06 1998-10-21 Abbott Laboratories Quinolizinone type compounds
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
AU3555200A (en) 1999-03-17 2000-10-04 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
US6375897B1 (en) 2000-02-14 2002-04-23 Ansys Technologies, Inc. Urine collection cup
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
CA2408343A1 (en) 2000-05-11 2002-11-07 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
SE0100326D0 (sv) 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
WO2002070527A1 (en) 2001-03-02 2002-09-12 Akzo Nobel N.V. Mass-selective purification of organometallics
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2003002561A1 (en) 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
US6455722B1 (en) 2001-06-29 2002-09-24 Pabu Services, Inc. Process for the production of pentaerythritol phosphate alcohol
GB2383315B (en) 2001-12-18 2005-04-06 Christopher Donald Clarke Vehicle imaging system
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
DE10226943A1 (de) 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
NZ538029A (en) 2002-07-09 2006-08-31 Actelion Pharmaceuticals Ltd 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives
JP4528125B2 (ja) 2002-10-11 2010-08-18 アクテリオン ファーマシューティカルズ リミテッド スルホニルアミノ−酢酸誘導体
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
DE602004021786D1 (de) 2003-03-26 2009-08-13 Actelion Pharmaceuticals Ltd Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
JP2007523846A (ja) 2003-04-28 2007-08-23 アクテリオン　ファマシューティカルズ　リミテッド キノキサリノン誘導体
US20040242641A1 (en) 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
WO2005005439A1 (en) 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2005023231A1 (en) 2003-09-10 2005-03-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
KR100848747B1 (ko) 2004-03-01 2008-07-25 액테리온 파마슈티칼 리미티드 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7226931B2 (en) 2004-07-22 2007-06-05 Cumbre Pharmaceuticals Inc. (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
CA2579227A1 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
WO2006056848A1 (en) 2004-11-24 2006-06-01 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
DE102004061344A1 (de) 2004-12-20 2006-07-06 Siemens Ag Verfahren zur sicheren Auslegung eines Systems, zugehörige Systemkomponente und Software
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
ES2434467T3 (es) 2005-05-13 2013-12-16 Lexicon Pharmaceuticals, Inc. Compuestos multicíclicos y métodos para su uso
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
US20080175795A1 (en) 2005-06-30 2008-07-24 Bexel Pharmaceuticals, Inc. Novel derivatives of amino acids for treatment of obesity and related disorders
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
EP1922071A2 (en) 2005-08-26 2008-05-21 Merck & Co., Inc. Diazaspirodecane orexin receptor antagonists
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20090105318A1 (en) 2006-03-29 2009-04-23 Coleman Paul J Amidoethylthioether Orexin Receptor Antagonists
CA2647678A1 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Diazepan orexin receptor antagonists
ATE496051T1 (de) 2006-04-26 2011-02-15 Actelion Pharmaceuticals Ltd Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
WO2007146761A2 (en) 2006-06-12 2007-12-21 Neurogen Corporation Diaryl pyrimidinones and related compounds
DK2049529T3 (da) 2006-07-14 2010-11-29 Merck Sharp & Dohme Substituerede diazepan-orexin-receptor- antagonister
US20100029736A1 (en) 2006-07-14 2010-02-04 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
AU2007272854B2 (en) 2006-07-14 2013-08-01 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
US7994336B2 (en) 2006-08-15 2011-08-09 Actelion Pharmaceuticals Ltd. Azetidine compounds as orexin receptor antagonists
ATE458740T1 (de) 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
JP2010503714A (ja) 2006-09-18 2010-02-04 エフ．ホフマン−ラ ロシュ アーゲー オクタヒドロピロロ［３，４−ｃ］ピロール誘導体、抗ウイルス剤としてのそれらの使用
CA2662612A1 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
EP2089018A2 (en) 2006-11-07 2009-08-19 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
US20110077200A1 (en) 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
EP2125823B1 (en) 2006-12-22 2012-02-15 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
JP2010525077A (ja) 2007-04-25 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 非塩基性メラニン凝集ホルモン受容体−１アンタゴニスト
AU2008255005B2 (en) 2007-05-18 2013-05-02 Merck Sharp & Dohme Corp. OXO bridged diazepan orexin receptor antagonists
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
TW200911242A (en) 2007-07-03 2009-03-16 Glaxo Group Ltd Novel compounds
EP2164847B1 (en) 2007-07-03 2011-09-14 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009011775A1 (en) 2007-07-13 2009-01-22 Merck & Co., Inc. Amidoethyl alkylamino orexin receptor antagonists
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
KR20100046047A (ko) 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
CN101801918A (zh) 2007-08-02 2010-08-11 弗·哈夫曼-拉罗切有限公司 作为食欲肽受体拮抗剂的单酰胺衍生物
AU2008288151A1 (en) 2007-08-15 2009-02-19 Actelion Pharmaceuticals Ltd 1,2-diamido-ethylene derivatives as orexin antagonists
CN101874030B (zh) 2007-09-24 2012-11-14 埃科特莱茵药品有限公司 用作食欲素受体拮抗剂的吡咯烷和哌啶
CA2703904A1 (en) 2007-10-29 2009-05-07 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
DE102007052177A1 (de) 2007-10-30 2009-05-07 Novega Produktionssysteme Gmbh Ortungsbake
EP2058001A1 (en) 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
BRPI0821141A2 (pt) 2007-12-21 2015-06-16 Hoffmann La Roche Derivados de heteroarila como antagonistas do receptor de orexina
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
US8598119B2 (en) 2008-05-27 2013-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
EP2303871B1 (en) 2008-07-29 2012-05-09 F. Hoffmann-La Roche AG Pyrrolidin-3-ylmethyl-amine as orexin antagonists
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
US20100267730A1 (en) 2008-10-09 2010-10-21 Giuseppe Alvaro Novel compounds
CA2739915A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
US8466281B2 (en) 2008-10-21 2013-06-18 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
EP2350061B1 (en) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
US8710076B2 (en) 2008-10-21 2014-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CA2739927A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
EP2348856B1 (en) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
EA201170624A1 (ru) 2008-10-30 2011-12-30 Мерк Шарп Энд Домэ Корп. Изоникотинамидные антагонисты рецепторов орексинов
CA2741648A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
JP2012507540A (ja) 2008-10-30 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション ピリダジンカルボキサミド・オレキシン受容体アンタゴニスト
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
WO2010060470A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
EP2358712A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
TW201033190A (en) 2008-12-02 2010-09-16 Glaxo Group Ltd Novel compounds
AR074426A1 (es) 2008-12-02 2011-01-19 Glaxo Group Ltd Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
US20100214135A1 (en) 2009-02-26 2010-08-26 Microsoft Corporation Dynamic rear-projected user interface
KR20120007061A (ko) 2009-04-24 2012-01-19 글락소 그룹 리미티드 오렉신 길항제로서 사용되는 3-아자비시클로［4.1.0］헵탄
JP2013502448A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド オレキシンアンタゴニストとして用いられるピペリジン誘導体
WO2011023578A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
ES2735411T3 (es) 2009-10-23 2019-12-18 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
AU2010310596B2 (en) 2009-10-24 2014-11-13 Indiana University Research And Technology Corporation Methods and compositions for panic disorders
TWI410630B (zh) 2009-11-10 2013-10-01 Ct Lab Inc 一種用以治療與食慾素受體１、食慾素受體２、體抑素受體２或多巴胺ｄ２ｌ受體相關之疾病的方法和組合物
JP5793505B2 (ja) 2009-12-23 2015-10-14 ジャスコ ファーマシューティカルズ， エルエルシー アミノピリミジンキナーゼ阻害薬
TW201307320A (zh) 2010-12-17 2013-02-16 大正製藥股份有限公司 吡唑衍生物
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
EP2708537A4 (en) 2011-05-10 2014-10-01 Taisho Pharmaceutical Co Ltd HETEROAROMATIC RING DERIVATIVE
EP2730573A4 (en) 2011-07-05 2014-12-03 Taisho Pharmaceutical Co Ltd METHYLPIPERIDINDERIVAT
US9029364B2 (en) 2011-10-21 2015-05-12 Merck Sharp & Dohme Corp. 2,5-disubstituted thiomorpholine orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
WO2013126856A1 (en) 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
HK1203197A1 (en) 2012-06-15 2015-10-23 Taisho Pharmaceutical Co., Ltd. Branched chain alkyl heteroaromatic ring derivative
JP2014015452A (ja) 2012-06-15 2014-01-30 Taisho Pharmaceutical Co Ltd ピラゾール誘導体を含有する医薬
RS55675B1 (sr) 2012-06-15 2017-06-30 Taisho Pharmaceutical Co Ltd Jedinjenja 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti oreksinskog receptora
JP2014111586A (ja) 2012-11-09 2014-06-19 Taisho Pharmaceutical Co Ltd ヘテロ芳香環誘導体を含有する医薬
EP2925321A4 (en) 2012-11-27 2016-04-27 Merck Sharp & Dohme 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
JP2016028017A (ja) 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2014141480A (ja) 2012-12-28 2014-08-07 Taisho Pharmaceutical Co Ltd メチルピペリジン誘導体を含有する医薬
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
WO2015018027A1 (en) 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Thiazole orexin receptor antagonists
IL321987A (en) 2013-12-03 2025-09-01 Intra Cellular Therapies Inc A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders
US9586934B2 (en) 2013-12-09 2017-03-07 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-methyl orexin receptor antagonists
JP2015131802A (ja) 2013-12-13 2015-07-23 大正製薬株式会社 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬
JP5930010B2 (ja) 2013-12-13 2016-06-08 大正製薬株式会社 ヘテロ芳香環メチル環状アミン誘導体を含有する医薬
WO2015095108A1 (en) 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Thioether-piperidinyl orexin receptor antagonists
TW201613891A (en) 2014-02-12 2016-04-16 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
JP2017100950A (ja) 2014-04-04 2017-06-08 大正製薬株式会社 オキソ複素環誘導体
JP2017100951A (ja) 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
WO2015180060A1 (zh) 2014-05-28 2015-12-03 杭州普晒医药科技有限公司 一种二氮杂环庚烷化合物的盐及其晶型与无定型物
ES2901418T3 (es) 2014-08-13 2022-03-22 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores del receptor de orexina
US20160051533A1 (en) 2014-08-20 2016-02-25 Ladd Research LLC Diagnosis and pharmacological treatment of seasonal affective disorder and symptoms of seasonality
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
CA2960253A1 (en) 2016-03-10 2017-09-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US20210169883A1 (en) 2018-07-27 2021-06-10 Icahn School Of Medicine At Mount Sinai Method of treating aggression with orexin receptor antagonists
GB201820458D0 (en) 2018-12-14 2019-01-30 Heptares Therapeutics Ltd Ox1 antagonists

Also Published As

Publication number Publication date
US20150335651A1 (en) 2015-11-26
EP2491038A1 (en) 2012-08-29
US12378254B2 (en) 2025-08-05
IL219234A (en) 2015-02-26
RS54945B1 (sr) 2016-11-30
KR101859400B1 (ko) 2018-05-18
AR114667A2 (es) 2020-09-30
US20120208812A1 (en) 2012-08-16
TWI481613B (zh) 2015-04-21
US8653263B2 (en) 2014-02-18
SI2491038T1 (sl) 2016-08-31
US11667644B2 (en) 2023-06-06
NI201200062A (es) 2013-04-19
CN102781942B (zh) 2015-09-23
NZ599629A (en) 2013-12-20
EA022766B1 (ru) 2016-02-29
CY1121848T1 (el) 2020-07-31
US20200048263A1 (en) 2020-02-13
KR20170136645A (ko) 2017-12-11
CR20120273A (es) 2012-10-25
PE20110404A1 (es) 2011-07-08
TW201217377A (en) 2012-05-01
JOP20180019A1 (ar) 2019-01-30
CL2010001162A1 (es) 2011-04-08
KR20120105449A (ko) 2012-09-25
AU2015242975A1 (en) 2015-11-05
EP3093291B1 (en) 2019-05-08
ES2735411T3 (es) 2019-12-18
TR201910327T4 (tr) 2019-07-22
SI3093291T1 (sl) 2019-08-30
HK1231463A1 (en) 2017-12-22
PT3093291T (pt) 2019-07-25
US20170129901A1 (en) 2017-05-11
USRE48841E1 (en) 2021-12-07
US11059828B2 (en) 2021-07-13
RS59004B1 (sr) 2019-08-30
AR078731A1 (es) 2011-11-30
JOP20180019B1 (ar) 2023-09-17
IL219234A0 (en) 2012-06-28
CA2778484C (en) 2018-07-31
AU2010310595A1 (en) 2012-05-17
ECSP12011908A (es) 2012-07-31
HUE043962T2 (hu) 2019-09-30
US20240109901A1 (en) 2024-04-04
PL3093291T3 (pl) 2019-11-29
US20140179697A1 (en) 2014-06-26
US9079911B2 (en) 2015-07-14
MX2012004753A (es) 2012-09-07
LT3093291T (lt) 2019-07-10
DK3093291T3 (da) 2019-07-29
KR101859409B1 (ko) 2018-05-18
HUE028650T2 (en) 2016-12-28
ME02437B (me) 2016-09-20
HK1175463A1 (zh) 2013-07-05
WO2011050198A1 (en) 2011-04-28
EP3581575A1 (en) 2019-12-18
HRP20191220T1 (hr) 2019-10-18
PT2491038T (pt) 2016-07-14
JO3267B1 (ar) 2018-09-16
BR112012010820A2 (pt) 2016-04-05
DK2491038T3 (da) 2016-07-18
BR112012010820B1 (pt) 2021-09-14
AU2015242975B2 (en) 2017-06-01
HRP20160781T1 (hr) 2016-09-23
UY32966A (es) 2011-04-29
EP2491038B1 (en) 2016-04-06
EP3093291A1 (en) 2016-11-16
ES2585806T3 (es) 2016-10-10
CY1117743T1 (el) 2017-05-17
CO6541572A2 (es) 2012-10-16
JP2013508403A (ja) 2013-03-07
KR20170135989A (ko) 2017-12-08
EA201270591A1 (ru) 2012-11-30
AU2010310595B2 (en) 2015-07-16
PH12012500796A1 (en) 2012-11-26
CN102781942A (zh) 2012-11-14
JP5759470B2 (ja) 2015-08-05
SMT201600216B (it) 2016-08-31
SMT201900392T1 (it) 2019-09-09
PL2491038T3 (pl) 2016-10-31
ME03452B (me) 2020-01-20
CA2778484A1 (en) 2011-04-28
US20210347781A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
UA107812C2 (xx) ДВОЗАМІЩЕНІ ОКТАГІДРОПІРОЛО$3,4-с]ПІРОЛИ ЯК МОДУЛЯТОРИ ОРЕКСИНОВИХ РЕЦЕПТОРІВ
MX2009012623A (es) Moduladores de cinasa heterociclicos.
TW200833692A (en) Triazolopyridazine protein kinase modulators
TW200745109A (en) Pyrrolo-pyridine kinase modulators
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
NZ629239A (en) Inhibitors of beta-secretase
MY162950A (en) Compounds and methods for kinase modulation, and indications therefor
PH12017501139A1 (en) Novel modulators and methods of use
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY173880A (en) Novel modulators and methods of use
AU2011328009A8 (en) Compounds and methods for treating pain
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112013005116A2 (pt) moduladores e métodos de uso
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
NZ602734A (en) Therapeutic dll4 binding proteins
MX2013005549A (es) Aminas heterociclicas y sus usos.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
MX2015002570A (es) Inhibidores de la beta-secretasa.
UY30666A1 (es) Trizoles biciclicos como moduladores de proteinquinasas